Conclusions This is the first prospective phase II trial of weekly nabPTX in combination with CBDCA in advanced NSCLC patients with ILD. This treatment showed favorable efficacy and was well tolerated. Clinical trial identification UMIN000012901. Legal entity responsible for the study The authors. ...
Methods Chemo-nave stage IIIB/IV or postoperative recurrent SCC pts were randomly assigned to receive either cisplatin (80 mg/m2) on day 1 plus gemcitabine (1000 mg/m2) on days 1, 8 every 3 weeks or CBDCA (AUC 6 mg/ml/min) on day 1 plus nab-PTX (75 mg/m2) on days 1, 8, ...
P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Nave Squamous Cell Lung Cancer: NJLCG1302doi:10.1016/j.jtho.2019.08.723T. HaradaY. KawashimaY. FujitaT. NakagawaK. WatanabeN. MorikawaK. Takamura...